March 24 (Reuters) - Medtronic ( MDT ) cut its profit

forecast for fiscal 2026 on Tuesday, citing a one-time charge of

about $157 million tied to payments related to a research

collaboration and the U.S. initial public offering of its

diabetes unit.

* The medical device maker expects 2026 adjusted profit per

share to be between $5.50 and $5.54, compared with $5.62 to

$5.66 forecast previously.

* Analysts estimate annual adjusted profit at $5.63 per

share, according to data compiled by LSEG.

* The charges were tied to payments under an R&D agreement

between Blackstone Life Sciences and Medtronic's ( MDT ) diabetes unit,

MiniMed, to fund the development of a smartphone-controlled

insulin pump, the company said.

* The U.S. Food and Drug Administration had cleared the

insulin pump, branded as MiniMed Flex, last week, a decision

that came several months earlier than anticipated.

* MiniMed debuted on Nasdaq earlier this month after

Medtronic ( MDT ) spun off the unit, which makes insulin pumps, glucose

monitors and sensors, to simplify its portfolio and concentrate

on higher-margin growth markets.

* Medtronic ( MDT ) said it does not expect the payments to impact

its fiscal 2027 results.